|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆĶô¼¿ ÄÚ¸®¾Æ CRA ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
05.16 |
|
|
(ÁÖ)À̳ë¹ÙÀÌ¿À½áÁö |
Ä¡°ú¿ë ÀÓÇöõÆ® Ç°Áú°ü¸®ÀÚ ¸ðÁýÇÕ´Ï´Ù.
´ëÀü À¯¼º±¸ | Çз¹«°ü |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
1³â¡è |
ä¿ë½Ã |
09.24 |
|
|
(ÁÖ)¼¼Á¾¾¾¾Ë¿À |
¼¼Á¾CRO - RA (Regulatory Affairs) ½ÅÀÔ ¹× °æ·ÂÀÚ ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
1³â¡è |
ä¿ë½Ã |
07.23 |
|
|
(ÁÖ)Çѱ¹ºñ¿¤¾àÇ° |
»ç¹«°æ¸®Á÷ Á÷¿ø±¸ÇÕ´Ï´Ù.
¼¿ï ¼ÛÆı¸ | °íµîÇб³ |
¼ö½Ãä¿ë |
1³â¡è |
ä¿ë½Ã |
02.06 |
|
|
ÇÁ·ÎÈÞ¸Õ |
»ý¸í°øÇÐ ¹× »ý¹°ÇÐ ºÐ¾ß ±â¼ú¿µ¾÷ ¸¶ÄÉÆà ´ã´çÀÚ Ã¤¿ë
¼¿ï ÀüÁö¿ª, ´ëÀü ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
2³â¡è |
ä¿ë½Ã |
03.11 |
|
|
¢ß¿ÀÅ亹ÄÚ¸®¾ÆÇコÄɾî |
¢ß¿ÀÅ亹ÄÚ¸®¾ÆÇコÄɾî - °í°´ÀüÈ»ó´ã ¸®¼Ä¡ (TM À¯°æÇè
¼¿ï °³²±¸ | Çз¹«°ü |
¸¶ÄÉÆÃ/±âȹ/±³À° |
1³â¡è |
ä¿ë½Ã |
03.31 |
|
|
ºñÀü¼Ä¡ |
ÀÇ·á±â±â(GIP, GMP) RA. ¿µ¾î°¡´ÉÀÚ
¼¿ï ±¤Áø±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
2³â¡è |
ä¿ë½Ã |
05.14 |
|
|
PharmaNet |
[Global CRO PharmaNet] °æ·Â CRA ±¸ÀÎ
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
03.30 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆĶô¼¿ ÄÚ¸®¾Æ -Local Enrolment Specialist (LES) /CRC Exp
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
10.18 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆÄ·º¼¿ ÄÚ¸®¾Æ- CRA ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
03.04 |
|
|
À⽺Å×À̼ÇÄÚ¸®¾Æ |
¶óÀ̼¾½ÌÆÀ ÀϺ»Áö¿ª ´ã´ç - ¸ÞÀÌÀú Á¦¾à»ç
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
¶óÀ̼¾½ºIn/Out |
2³â¡è |
ä¿ë½Ã |
07.16 |
|
|
ÆÄÀÌÄ«Ä¡¸ÞµðÄ® |
¿µ¾÷Á÷¿ø ¸ðÁýÇÕ´Ï´Ù
°æ±â ±èÆ÷½Ã | °íµîÇб³ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
1³â¡è |
ä¿ë½Ã |
03.15 |
|
|
ÆĶó°ïÄÁ¼³Æà |
ÀǾàÇ° ÀÎÇã°¡ ¾÷¹«(RA/QA) ´ã´çÀÚ ¸ðÁý
¼¿ï ¿µµîÆ÷±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
1³â¡è |
ä¿ë½Ã |
05.31 |
|
|
(ÁÖ)»ï¹ÌÄ· |
ÈÀåÇ°¿ë ¿ø·á ±â¼ú¿µ¾÷
°æ±â ¼º³²½Ã Áß¿ø±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
09.26 |
|
|
ÁÖ½Äȸ»ç ºÎ»ê¿¡À̽ºÆĸ¶ |
½ÅÀÔ¹× °æ·Â»ç¿ø¸ðÁýÇÕ´Ï´Ù
ºÎ»ê ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
1³â¡è |
ä¿ë½Ã |
08.23 |
|